Written reports

Written reports
2020-10-27 - 2020-10-28
Online, Virtual
PAINWeek 2020

PAINWeek 2020
2020-09-11 - 2020-09-13
Online, Virtual
EULAR 2020

EULAR 2020
2020-06-03 - 2020-06-06
Online, Virtual
EASD 2019

EASD 2019
2019-09-16 - 2019-09-20
Barcelona, Spain
ESH 2019

ESH 2019
2019-06-21 - 2019-06-24
Milan, Italy
EASD 2018

EASD 2018
2018-10-01 - 2018-10-05
Berlin, Germany
ESH 2018

ESH 2018
2018-06-08 - 2018-06-11
Barcelona, Spain
EAS 2018

EAS 2018
2018-05-05 - 2018-05-08
Lisbon, Portugal
MHT 2017

MHT 2017
2017-09-29 - 2017-09-30
Siófok, Hungary
Search in Scientific Content:
Date
Filters:
Which are
4:59
Title Description

Which are the most promising new medications in phase 3 clinical trials for the treatment of painful large joint arthritis?

Presenter: Nancy Lane
PAINWeek 2020
What is th
14:04
Title Description

What is the role of transdermal fentanyl patches in management of cancer pain?

Presenter: Mellar P. Davis
PAINWeek 2020
Optimising
8:42
Title Description

Optimising the monitoring and treatment of SSc-ILD

Presenter: Anna-Maria Hoffmann
EULAR 2020
Highlights
12:44

Highlights of the 2019 EASD Congress

Presenter: David R. Matthews
Specialty: Diabetes
EASD 2019
DAPA HF : ...
3:22

DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial

Presenter: John McMurray
Specialty: Diabetes
EASD 2019
Early inte
10:09

Early intervention with oral semaglutide and long term safety

Presenter: Melanie Davies
Specialty: Diabetes
EASD 2019
VERIFY and
3:57

VERIFY and CONCLUDE study

Presenter: Stefano Del Prato
Specialty: Diabetes
EASD 2019
Cardio-ren
15:01

Cardio-renal risk

Presenter: Tina Vilsbøll
Specialty: Diabetes
EASD 2019
Clinical p
4:13

Clinical properties and differences between GLP-1 agonists

Presenter: Michael A. Nauck
Specialty: Diabetes
EASD 2019
Why We Sho
8:36

Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes

Presenter: Hertzel Gerstein
Specialty: Diabetes
EASD 2019
Diabetic r
7:57

Diabetic retinopathy: Is the eye a mirror of the brain?

Presenter: Coen D. A. Stehouwer
Specialty: Diabetes
EASD 2019
Cardiovasc
7:42

Cardiovascular risk factors

Presenter: Gian Paolo Rossi
ESH 2019
Leading ro
7:42

Leading role of hypertension in CV risk scene

Presenter: Enrico Agabiti Rosei
ESH 2019
Controvers
3:07

Controversial issues in guidelines

Presenter: Anna F. Dominiczak
ESH 2019
Cardiovasc
3:32

Cardiovascular mode of action of GLP-1 receptor agonists

Presenter: Jorge Plutzky
Specialty: Diabetes
EASD 2018
Exploring
6:34

Exploring the effects of SGLT2 inhibition in ongoing clinical trials

Presenter: Stefan D. Anker
Specialty: Diabetes
EASD 2018
Medical De
9:40

Medical Devices in Diabetes

Presenter: Anne Louise Peters
Specialty: Diabetes
Will SGLT2
9:12

Will SGLT2-inhibitors change the landscape?

Presenter: Apostolos Tsapas
Specialty: Diabetes
Innate imm
10:54

Innate immunity in pancreatic islet inflammation

Presenter: Decio L. Eizirik
Specialty: Diabetes
The artifi
5:30

The artificial beta cell. When will the dream become reality?

Presenter: Eric Renard
Specialty: Diabetes
Observatio
6:15

Observational study of insulin pump treatment

Presenter: Soffia Gudbjörnsdottir
Specialty: Diabetes
The eviden
7:34

The evidence for metformin is unclear?

Presenter: Rury Holman
Specialty: Diabetes
The ORIGIN
10:10

The ORIGIN Study And Legacy Effects

Presenter: Hertzel Gerstein
Specialty: Diabetes
EMPA-REG O
11:11

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Presenter: Hans-Juergen Woerle
Specialty: Diabetes
Principal
10:00

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Presenter: Bernard Zinman
Specialty: Diabetes
Mathematic
7:40

Mathematic modelling of fibrinolysis

Presenter: Brittany Bannish
Pre and pe
2:02

Pre and perioperative factors modulate fibrinolysis in arthroplasty patients

Presenter: Drew Burleson
Cellular a
31:38

Cellular and mechanical modulators of fibrin structure

Presenter: Kraszimir Kolev
Platelets,
41:33

Platelets, NETs and Immunity

Presenter: Paul Kubes
Mechanisms
17:59

Mechanisms by which DNA, histones and NETs stabilise clots

Presenter: Imre Varju
Free fatty
3:31

Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots

Presenter: Anna Tanka-Salamon
Genetics o
31:21

Genetics of thrombosis

Presenter: David Ginsburg